Zhang Meiqi, Han Zhongyu, Lin Yumeng, Jin Zi, Zhou Shuwei, Wang Siyu, Tang Yuping, Li Jiaxuan, Li Xueping, Chen Haoran
School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Naniing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.
Front Microbiol. 2024 Jun 28;15:1418301. doi: 10.3389/fmicb.2024.1418301. eCollection 2024.
Hepatitis C virus (HCV) can cause a range of kidney diseases. HCV is the primary cause of mixed cryoglobulinaemia, which leads to cryoglobulinaemic vasculitis and cryoglobulinaemic glomerulonephritis (GN). Patients with acute cryoglobulinaemic vasculitis often exhibit acute kidney disease due to HCV infection, which typically progresses to acute kidney injury (AKI). HCV also increases the risk of chronic kidney disease (CKD) and the likelihood of developing end-stage renal disease (ESRD). Currently, direct-acting antiviral agents (DAAs) can be used to treat kidney disease at different stages. This review focuses on key findings regarding HCV and kidney disease, discusses the impact of DAAs, and highlights the need for further research and treatment.
丙型肝炎病毒(HCV)可引发一系列肾脏疾病。HCV是混合性冷球蛋白血症的主要病因,混合性冷球蛋白血症会导致冷球蛋白血症性血管炎和冷球蛋白血症性肾小球肾炎(GN)。急性冷球蛋白血症性血管炎患者常因HCV感染而出现急性肾脏疾病,这种疾病通常会进展为急性肾损伤(AKI)。HCV还会增加慢性肾脏病(CKD)的风险以及发展为终末期肾病(ESRD)的可能性。目前,直接作用抗病毒药物(DAAs)可用于治疗不同阶段的肾脏疾病。本综述聚焦于HCV与肾脏疾病的关键研究结果,讨论DAAs的影响,并强调进一步研究和治疗的必要性。